Novo Nordisk
-
Switching to Tresiba® benefits people with diabetes irrespective of blood sugar levels
Dec 6, 2017In patients with uncontrolled type 1 or type 2 diabetes, switching to Tresiba® resulted in significantly improved glycaemic control without an increase in the risk of hypoglycemia or insulin dose. Switching to Tresiba® from another basal... -
The U.S. Food and Drug Administration approved Novo Nordisk’s diabetes drug Ozempic
Dec 6, 2017Ozempic, known generically as semaglutide, will compete with others in a class known as glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin. The U.S. Food and Drug Administration on... -
Switching to Tresiba® is highly cost-effective and cost-saving in a real-world setting
Nov 6, 2017News Hour: A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.1 The analysis was presented... -
FDA approves Novo Nordisk’s Fiasp®
Oct 1, 2017News Hour: Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA’s decision comes... -
Novo Nordisk’s new-generation basal insulin Tresiba® approved in China
Sep 27, 2017News Hour: Novo Nordisk today announced that the China Food and Drug Administration (CFDA) has approved Tresiba® (insulin degludec) for the treatment of diabetes in China. Tresiba® is a new-generation, once-daily basal insulin with an ultra-long duration of action which allows... -
Tresiba® trial shows that people with type 2 diabetes who avoid severe hypoglycaemia have a reduced risk of deat
Sep 16, 2017News Hour: Novo Nordisk announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycemia (low blood sugar levels) are at greater risk of death. The risk... -
Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term
Sep 15, 2017News Hour: Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar and post-meal sugar control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings. The findings... -
FDA approved a new indication for Victoza® to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes
Aug 31, 2017News Hour: The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV... -
FDA approved expanded use of Novo Nordisk diabetes drug to reduce the risk of cardiovascular events
Aug 26, 2017News Hour: Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke. This... -
Tresiba® demonstrated no increased risk of major cardiovascular events
Jun 17, 2017News Hour: Tresiba® demonstrated no increased risk of major cardiovascular (CV) events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial. DEVOTE is a long-term, a multinational, randomized,...
